Comparative Pharmacology
Head-to-head clinical analysis: TESTOPEL versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOPEL versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
TESTOPEL vs TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Category C
Category D/X
Androgen
Androgen